Current Headlines

  1. GNQ Insilico Launches Revolutionary AI-Driven Assessment Platform To Transform Precision Medicine And Drug Development 9/11/2025

    GNQ Insilico Inc. (“GNQ” or “the Company”), a pioneering TechBio firm leveraging exponential technologies for precision medicine, announces the official launch of its groundbreaking deep tech Drug Assessment Platform (DAP).

  2. Absci Accelerates AI-Driven Drug Discovery With Oracle And AMD 9/11/2025

    Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery.

  3. FDA Files Corcept's New Drug Application For Relacorilant As A Treatment For Patients With Platinum-Resistant Ovarian Cancer 9/10/2025

    Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has accepted Corcept’s New Drug Application (NDA) for relacorilant as a treatment for patients with platinum-resistant ovarian cancer

  4. Symeres Acquires DGr Pharma To Enhance Regulatory Expertise And Broaden Its Biopharma Capabilities 9/10/2025

    Symeres, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients.

  5. Lilly Launches TuneLab Platform To Give Biotechnology Companies Access To AI-Enabled Drug Discovery Models Built Through Over $1B In Research Investment 9/9/2025

    Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly's research data.

  6. XtalPi AI Drug Discovery Collaboration Reaches Milestone As PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals 9/9/2025

    XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors.

  7. insitro Partners With Lilly To Build First-In-Kind Machine Learning Models To Advance Small Molecule Drug Discovery 9/9/2025

    insitro, a pioneer in machine learning for drug discovery and development, today announced a new collaboration with Eli Lilly and Company (Lilly) to develop advanced machine learning models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo.

  8. Lunai Bioworks Inc. Unveils Transformer Platform To Secure Generative AI And Accelerate Drug Discovery 9/9/2025

    Lunai Bioworks Inc., an AI-powered drug discovery and biodefense company, today announced the launch of a transformer-based platform that embeds biological risk intelligence directly into large language model (LLM) pipelines.

  9. Teva's Emrusolmin Granted U.S. FDA Fast Track Designation For Treatment Of Multiple System Atrophy 9/9/2025

    Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Teva’s investigational therapy emrusolmin (TEV-56286) for the treatment of Multiple System Atrophy (MSA).

  10. New UMaine Research Could Help Lower Prescription Drug Costs 9/8/2025

    One of the main factors driving prices in pharmaceuticals, such as cholesterol-lowering drugs and antibiotics, is the cost of production and materials.